🔴 PFE.BA is trading 0% down today as shares ease following a rally on FDA approval for its IBRANCE regimen

PFE.BA is trading at $9135 (0%) as the stock stabilizes following a two-day slide that retraced gains from earlier in the week.

• The recent volatility follows the FDA's expanded approval for Pfizer’s IBRANCE, making it the first CDK4/6 inhibitor approved for HR+ metastatic breast cancer regardless of HER2 status.
• While shares have eased from their weekly highs, the expanded indication significantly strengthens Pfizer’s oncology franchise and market positioning.
• The drug's new status is expected to bolster long-term growth for the company's cancer treatment portfolio.